SCIRENT, a full-service contract research organization (CRO) specializing in cardiovascular trials, is joining forces with CCS, a US-based cardiovascular clinical research organization, at HFSA Annual Scientific Meeting 2022 in Washington. Come and meet us at booth 228 from September 30, 2022 – October 3, 2022, to learn more about our industry-leading cardiovascular research services and patient recruitment […]
10.08.2022. SCIRENT is excited to participate at the ESC Congress 2022 in Barcelona, which is taking place from 26-29 August 2022. Please book an appointment with our leadership to learn more about our industry-leading cardiovascular research services and patient recruitment capabilities. SCIRENT is a specialty CRO focused on cardiovascular research. We offer an excellent network […]
10.11.2021. SCIRENT is attending the American Heart Association’s Scientific Sessions, AHA 2021, from November 13-15, 2021 as a proud exhibitor. Visit our booth and connect with us live to learn more about our industry-leading cardiovascular research services, patient recruitment capabilities, and study experience. The American Heart Association’s Scientific Sessions 2021 is the largest cardiovascular meeting […]
BERLIN, Sept. 21, 2021 /PRNewswire/ — SCIRENT, an international full-service cardiovascular contract research organization (CRO), is proud to appoint Dr. Maximilian Posch as Chief Medical Officer. In his new position, Dr. Posch will be an important driver of SCIRENT’s growth by contributing medical and scientific expertise to support SCIRENT’s service portfolio and consulting clients on […]
Berlin Heals’ innovative implantable C-MIC device delivers encouraging clinical results in the treatment of heart failure.
Restarting by Design: Agile Crisis Management for Rapid Resumption of Cardiovascular Clinical Trials
The entire landscape of hospital-based clinical trials dramatically changed when COVID-19 singlehandedly stopped the global recruitment of ongoing cardiovascular trials. Heart failure clinical trials were already subject to factors such as regional variation in clinical practice, trial implementation, and patient characteristics, which drive event rate and treatment effect size assumptions key to demonstrating clinical benefit. […]
SCIRENT and Virtonomy Announce Joint Efforts to Advance Use of Virtual Patients in Medical Device Clinical Trials
SCIRENT, a full-service contract research organization (CRO) specialized in cardiovascular trials, and Virtonomy, a pioneer in developing data-driven clinical trials using virtual patients, announced today their cooperation on the use of virtual patients in medical device clinical trials. Both companies offer services for the development of medical devices. By working together, valuable time and financial resources […]
Global medical technology and innovation company, LivaNova PLC, conducts the large medical device study ANTHEM-HFrEF to evaluate whether autonomic regulation therapy will benefit patients with symptomatic heart failure and reduced ejection fraction. The trial is performed by the US-based CRO CCSF, with SCIRENT responsible for managing the European sites. The prospective, international, randomized, controlled clinical […]
Drug developer Berlin Cures has launched a phase IIa trial for its β1-adrenoceptor autoantibody (β1-AAb) neutralizing ssDNA product BC 007.
The global COVID-19 pandemic has largely impacted the healthcare system and also the conduct of clinical trials. Many sponsors have had to adapt clinical trial operations to the changing conditions of the pandemic, causing major disruptions in trial conduct. Some trials have had to face the shutdown of trial sites, limited access to regulatory bodies, […]